Clinical Trials › NCT05441488
Active, Not RecruitingPhase 3
Masitinib in the Treatment of Patients With Primary Progressive or Non-active Secondary Progressive Multiple Sclerosis
Sponsored by AB Science
Interested in joining? Eligibility criteria and contact info are on ClinicalTrials.gov.
View on ClinicalTrials.gov 800
Target enrollment
Jun 2022
Start date
Dec 2028
Expected completion
Interventions / Treatments
PlaceboMasitinib (4.5)
Conditions studied
Progressive Multiple Sclerosis
Trial locations
U.S. site locations haven't been posted yet for this trial. Check ClinicalTrials.gov for the latest contact and location info.
More Phase 3 trials
Browse all Phase 3 MS trialsThe app
Check out the MS Buddy app
Track symptoms, monitor wellness, and stay on top of your MS care. It’s free, with no ads. Built by people living with MS.